Meeting
2018 ASCO Annual Meeting
Phase 1/2 intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.
Authors
Cornelis Martinus van Tilburg
KiTZ Clinical Trial Unit, Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany
Cornelis Martinus van Tilburg , Till Milde , Angelika Seitz , Jens-Peter Schenk , Michael Fruehwald , Arnulf Pekrun , Claudia Rössig , Regina Wieland , Christian Flotho , Uwe Kordes , Bernd Gruhn , Thorsten Simon , Christin Linderkamp , Lenka Taylor , Juergen Burhenne , Stefan M. Pfister , Irini Karapanagiotou-Schenkel , Olaf Witt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01422499
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10535)
DOI
10.1200/JCO.2018.36.15_suppl.10535
Abstract #
10535
Poster Bd #
208
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2022 ASCO Annual Meeting
Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors.
First Author: Alexander Starodub
Poster
2017 ASCO Annual Meeting
Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas.
First Author: Geraldine Helen O'Sullivan Coyne
Poster
2011 ASCO Annual Meeting
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study.
First Author: T. R. Hummel